CAR T-Cell Therapy: Changing the Treatment Landscape for Hematologic Malignancies

Download All
In this engaging online program, watch experts discuss emerging strategies and current best practices in CAR T-cell therapy for patients with lymphomas, leukemias, and myelomas. Download slides with all the key data, view the on-demand Webcast, and join the discussion with expert-authored commentaries and podcasts.
Jeremy S. Abramson, MD, MMSc

ClinicalThought

With the approval of lisocabtagene maraleucel, another CAR T-cell therapy option is now available for patients with relapsed/refractory lymphomas. Review this expert commentary on how to incorporate this agent into your practice.

Jeremy S. Abramson, MD, MMSc Released: March 12, 2021
Provided by Medical College of Wisconsin in partnership with Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Bristol-Myers Squibb
Kite Pharma

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue